Analysts’ Weekly Ratings Changes for Arvinas (ARVN)

Posted by Brenda Bartman on Aug 26th, 2026

Arvinas (NASDAQ: ARVN) has recently received a number of price target changes and ratings updates:

8/13/2026 – Arvinas was upgraded by Weiss Ratings from “sell (e+)” to “sell (d)”.
8/10/2026 – Arvinas was given a new $10.00 price target by Morgan Stanley.
8/10/2026 – Arvinas was given a new $14.00 price target by Evercore Inc.
8/10/2026 – Arvinas had its price target lowered by Citigroup Inc. from $24.00 to $21.00. They now have a “buy” rating on the stock.
8/8/2026 – Arvinas was upgraded by Wall Street Zen from “sell” to “hold”.
8/5/2026 – Arvinas had its price target raised by Wedbush from $11.00 to $12.00. They now have a “neutral” rating on the stock.
8/5/2026 – Arvinas was upgraded by Zacks Research from “hold” to “strong-buy”.
8/4/2026 – Arvinas had its “equal weight” rating reaffirmed by Wells Fargo & Company. They now have a $11.00 price target on the stock, down from $15.00.
8/4/2026 – Arvinas was downgraded by Wells Fargo & Company from “overweight” to “equal weight”.
8/4/2026 – Arvinas had its “buy” rating reaffirmed by BTIG Research. They now have a $18.00 price target on the stock.
7/30/2026 – Arvinas was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
7/26/2026 – Arvinas was upgraded by Wall Street Zen from “strong sell” to “sell”.
7/18/2026 – Arvinas was downgraded by Wall Street Zen from “sell” to “strong sell”.
7/13/2026 – Arvinas was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.

Insider Buying and Selling

In related news, CFO Andrew Saik sold 5,696 shares of Arvinas stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $8.16, for a total value of $46,479.36. Following the completion of the sale, the chief financial officer directly owned 187,432 shares in the company, valued at $1,529,445.12. This trade represents a 2.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 7.30% of the stock is currently owned by insiders.

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.

Analysts’ Weekly Ratings Changes for Arvinas (ARVN)

Insider Buying and Selling

See Also

You might be interested in: